OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Ado-tratuzumab emtansine beyond breast cancer: therapeutic role of targeting other HER2-positive cancers
Zheng Yang, Jiayu Zou, Chen Sun, et al.
Frontiers in Molecular Biosciences (2023) Vol. 10
Open Access | Times Cited: 6
Zheng Yang, Jiayu Zou, Chen Sun, et al.
Frontiers in Molecular Biosciences (2023) Vol. 10
Open Access | Times Cited: 6
Showing 6 citing articles:
Advances in Drug Targeting, Drug Delivery, and Nanotechnology Applications: Therapeutic Significance in Cancer Treatment
Fatih Çiftçi, Ali Can Özarslan, İmran Cagri Kantarci, et al.
Pharmaceutics (2025) Vol. 17, Iss. 1, pp. 121-121
Open Access | Times Cited: 1
Fatih Çiftçi, Ali Can Özarslan, İmran Cagri Kantarci, et al.
Pharmaceutics (2025) Vol. 17, Iss. 1, pp. 121-121
Open Access | Times Cited: 1
Antitumor activities against breast cancers by an afucosylated anti‐HER2 monoclonal antibody H2Mab‐77‐mG2a ‐f
Tomohiro Tanaka, Hiroyuki Suzuki, Tomokazu Ohishi, et al.
Cancer Science (2023) Vol. 115, Iss. 1, pp. 298-309
Open Access | Times Cited: 7
Tomohiro Tanaka, Hiroyuki Suzuki, Tomokazu Ohishi, et al.
Cancer Science (2023) Vol. 115, Iss. 1, pp. 298-309
Open Access | Times Cited: 7
Antitumor Activities against Breast Cancers by an Afucosylated Anti-HER2 Monoclonal Antibody H<sub>2</sub>Mab-77-mG<sub>2a</sub>-f
Tomohiro Tanaka, Hiroyuki Suzuki, Tomokazu Ohishi, et al.
(2023)
Open Access | Times Cited: 6
Tomohiro Tanaka, Hiroyuki Suzuki, Tomokazu Ohishi, et al.
(2023)
Open Access | Times Cited: 6
Targeting HER2 and FGFR-positive cancer cells with a bispecific cytotoxic conjugate combining anti-HER2 Affibody and FGF2
Mateusz Adam Krzyścik, Natalia Porębska, Łukasz Opaliński, et al.
International Journal of Biological Macromolecules (2023) Vol. 254, pp. 127657-127657
Open Access | Times Cited: 3
Mateusz Adam Krzyścik, Natalia Porębska, Łukasz Opaliński, et al.
International Journal of Biological Macromolecules (2023) Vol. 254, pp. 127657-127657
Open Access | Times Cited: 3
Neuropilin-1: A Promising Therapeutic Target for Triple-Negative Breast Cancer
Noura Al‐Zeheimi, Sirin A. Adham
IntechOpen eBooks (2024)
Closed Access
Noura Al‐Zeheimi, Sirin A. Adham
IntechOpen eBooks (2024)
Closed Access
Evaluation of the Safety and Efficacy of Trastuzumab Emtansine (T-DM1) Biosimilar in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer: Findings From a Single-Center Retrospective Analysis in India
Kaushal Patel, Vipulkumar Thummar, Priya Mehta
Cureus (2024)
Open Access
Kaushal Patel, Vipulkumar Thummar, Priya Mehta
Cureus (2024)
Open Access
